GSK bribery probe extends to Jordan and Lebanon; Novartis mistakenly announces approval of drug FDA has not yet ruled on;

@FiercePharma: Top-read special report yesterday: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. Story via MediaPost | Follow @TracyStaton

@EricPFierce: Pacira invests $40M to $50M in a DPx U.K. plant, allowing it to produce an additional $300M in Exparel. Article via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: So there are no anthropomorphized body parts in this week's FiercePharmaMarketing, but Viagra-flavored ice cream does make an appearance. Edition | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) says it's investigating bribery allegations in Jordan and Lebanon, following earlier claims of corruption in China, Iraq and Poland. Story

> Boehringer Ingelheim, joining other drugmakers in improving clinical trial transparency, says it will make its data available going back to 1998. Story

> Novartis ($NVS) accidentally sent out a mass email announcing the FDA approval of lung cancer drug Zykadia--a drug the agency has not actually approved yet. News

> The FDA wants drugmakers and others to weigh in on its ideas for its new strategy for health IT products. Blog post

> Teva ($TEVA) has launched a generic of Sunovion's insomnia treatment Lunesta. Report

Medical Device News

@FierceMedDev: Report: Cardiac Dimensions raises $20M for heart valve sales in Europe. Story | Follow @FierceMedDev

@VarunSaxena2: FierceBiotech broke story on Novartis stopping RNAi research. I'm interviewing Alnylam on fallout. $ALNY down 20+% since last week. | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific scores FDA approval for a new crop of implantable cardiac devices. News | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article via FierceDrugDelivery | Follow @MichaelGFierce

> St. Jude rides strong ICD sales to a first-quarter bump. More

> Qiagen puts up $10M to boost its diagnostics manufacturing. Piece

Biotech News

@FierceBiotech: Have the biotech bears run out of steam? Item | Follow @FierceBiotech

@JohnCFierce: Column Group nears goal line for $250M biotech venture fund. More | Follow @JohnCFierce

@DamianFierce: TriVascular's IPO prices at $12, below its range, and raises $78 million. Release | Follow @DamianFierce

@EmilyMFierce: ICYMI: Latest issue of FierceBiotech Research features 3-D printing to study cancer and Silly Putty to grow stem cells. More | Follow @EmilyMFierce

> Baxter's latest bleeding drug hits the mark in PhIII. Story

> BioAlliance and Topotarget plan to merge, pooling their cancer pipelines. More

> VCs gamble $96M on rare disease drug, biosimilar play and new drug for AMD. Article

Drug Delivery News

> Study shows nanoparticles can lose their uniform shape, size under lab conditions. More

> Alliqua pulls in $20M to support hydrogel wound care biz. Item

> MIT team delivers three ovarian cancer drugs with one particle. Story

> Magnetic anesthesia: Delivering nerve blocks locally with a targeted approach. Article

> Study: Inhalable encapsulated antibiotic from Aradigm kills 99% of infections. Report

> Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate.' News

Diagnostics News

> Philips touts encouraging results from an early test of its hand-held cardiac blood Dx. More

> UCLA, working with a Chinese partner, will build a high-tech Dx lab in Shanghai. Story

> Qiagen licenses biomarker for rare blood disorders with a molecular Dx in mind. Article

> GE Healthcare's Dineen: A quest for new acquisitions will continue. News

> Sequenom scores a blow against Illumina in prenatal Dx patent fight. More

> An acquisition helps carry ERBA Diagnostics to a (small) 2013 profit. Item

Pharma Marketing News

> Pharma sales force took a hit in North America and Europe in 2013, new report shows. More

> BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency. Story

> How to talk about constipation? Forest's new DTC campaign for Linzess will show you. Article

> Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market. News

> Sanofi beefs up social media channels with Spanish Twitter push. Report

> GlaxoSmithKline bribery probe heats up as Polish prosecutors charge 13 people. Item

And Finally... Sanofi ($SNY) has brought on former WNBA star and coach Nancy Lieberman to help promote its OTC version of allergy med Nasacort, a move it says will help allergy sufferers "put the full 'cort press" on symptoms. Release

Editor's Note: An image in Monday's FiercePharma report should have shown GlaxoSmithKline's headquarters rather than AstraZeneca's to go along with this story. We regret the error and apologize for any confusion.

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.